Interv Akut Kardiol. 2020;19(4):236-237 | DOI: 10.36290/kar.2020.050

Administration of cangrelor after coronary intervention immediately following minimally invasive cardiac surgery procedure

Martin Mates1, ©těpán Černý2, Karel Kopřiva1
1 Kardiologické oddělení, Komplexní kardiovaskulární centrum, Nemocnice Na Homolce, Praha
2 Kardiochirurgické oddělení, Komplexní kardiovaskulární centrum, Nemocnice Na Homolce, Praha

The case report describes the administration of cangrelor to a female patient who underwent percutaneous coronary intervention with stent implantation immediately following a minimally invasive cardiac surgery procedure (mitral and tricuspid valvuloplasty). The reasons for administering a parenteral antiplatelet agent were bleeding concerns and impossibility of oral intake.

Keywords: percutaneous coronary intervention, stent, cangrelor, cardiac surgery.

Published: December 3, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mates M, Černý ©, Kopřiva K. Administration of cangrelor after coronary intervention immediately following minimally invasive cardiac surgery procedure. Interv Akut Kardiol. 2020;19(4):236-237. doi: 10.36290/kar.2020.050.
Zobrazit celý článek

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Steg PG, Bhatt DL, Hamm CW, et al. CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013; 382: 1981-1992. Go to original source...
    2. Mates M, Němec P, ®elízko M, et al. Doporučené postupy ESC/EACTS pro revaskularizaci myokardu, 2018. Souhrn dokumentu připravený Českou kardiologickou společností, Českou asociací intervenční kardiologie a Českou společností kardiovaskulární chirurgie ČLS JEP. Cor Vasa 2019; 61: e123-e156.
    3. Venugopal BB Gaddam S, Lassiter MA, et al. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events Ann Transl Med 2019; 7(17): 408. doi: 10.21037/atm.2019.07.64. Go to original source... Go to PubMed...
    4. Angiolillo DJ, Firstenberg MS, Price MJ. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012; 307(3): 265-274. doi: 10.1001/jama.2011.2002. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.